Showing 5511-5520 of 5771 results for "".
- Data from BioTime’s OpRegen Program to Be Presented at AAO 2018https://modernod.com/news/data-from-biotimes-opregen-program-to-be-presented-at-aao-2018/2479983/BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30
- Genentech Unveils New Clinical Data For the First Eye Implant for Wet AMDhttps://modernod.com/news/genentech-unveils-positive-phase-2-results-for-the-first-eye-implant-for-wet-amd/2479987/Genentech announced positive topline results from the phase 2 LADDER study evaluating the efficacy and safety of its investigational Port Delivery System (PDS) with ranibizumab in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly l
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and
- Eton Pharma Reports Positive Topline Results from Phase 3 Trial of EM-100https://modernod.com/news/eton-pharma-reports-positive-topline-results-from-phase-3-trial-of-em-100/2479990/Eton Pharmaceuticals announced positive topline results for its phase 3 study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Aura Biosciences Presents Interim Phase 1b/2 Data at ASRShttps://modernod.com/news/aura-biosciences-presents-interim-phase-1b-2-data-at-asrs/2479994/Aura Biosciences presented interim data from an open-label phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary choroidal melanoma, at the 36th annual American Society of Retina Specialists (ASRS) meeting in Vancouver, Canada. The findings were presented by Am
- Thomas A. Finley, MD, Appointed Chairmen of Ocutrx International Medical Advisory Boardhttps://modernod.com/news/thomas-a-finley-md-appointed-chairmen-of-ocutrx-international-medical-advisory-board/2479996/Ocutrx Vision Technologies, a California-based augmented reality (AR) glasses developer announced that Thomas A. Finley, MD, will serve as the Chairman of the Ocutrx International Medical Advisory Board (IMAB). The board serves to advise Ocutrx in its development of augmented reality glasses for
- Omeros Corporation Initiates Sales of Omidria in Europehttps://modernod.com/news/omeros-corporation-initiates-sales-of-omidria-in-europe/2479997/Omeros announced initial sales of »Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. Omidria, approved and commercially available in the United
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Pattern Scanning Laser Trabeculoplasty Program Obtains FDA Clearance for the Pascal Synthesis and TwinStarhttps://modernod.com/news/pattern-scanning-laser-trabeculoplasty-program-obtains-fda-clearance-for-the-pascal-synthesis-and-twinstar/2480002/Topcon Medical Systems announced that its proprietary software, Pattern Scanning Laser Trabeculoplasty (PSLT), for the reduction of IOP associated with glaucoma, has obtained FDA clearance for use with the